Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Cel-Sci Corp (CVM)

Cel-Sci Corp (CVM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 518,334
  • Shares Outstanding, K 38,624
  • Annual Sales, $ 460 K
  • Annual Income, $ -22,130 K
  • 60-Month Beta 2.15
  • Price/Sales 1,123.68
  • Price/Cash Flow N/A
  • Price/Book 26.66

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.29 +17.44%
on 09/15/20
14.50 -8.55%
on 09/21/20
+0.51 (+4.00%)
since 08/21/20
3-Month
11.29 +17.44%
on 09/15/20
17.10 -22.46%
on 06/25/20
-1.76 (-11.72%)
since 06/23/20
52-Week
6.00 +121.00%
on 10/24/19
18.00 -26.33%
on 05/04/20
+4.71 (+55.09%)
since 09/23/19

Most Recent Stories

More News
CEL-SCI Awarded European Patent for LEAPS Vaccine in Treatment of Rheumatoid Arthritis

CEL-SCI Corporation (NYSE American: CVM) today announced that the European Patent Office has issued CEL-SCI patent: European Patent 2989121 to be published on October 7, 2020, and titled "Method of Preparation...

CVM : 13.19 (-1.71%)
CEL-SCI Corporation Issues Letter to Shareholders

CEL-SCI Corporation (NYSE American: CVM) today issued a letter to its shareholders.

CVM : 13.19 (-1.71%)
CEL-SCI Corporation to Present at H.C. Wainwright 22nd Annual Global Investment Conference

CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced that it will be presenting at the H.C. Wainwright 22nd Annual Global Investment Conference. The virtual...

CVM : 13.19 (-1.71%)
CEL-SCI Corporation to Present at The LD 500 Virtual Conference

VIENNA, VA / ACCESSWIRE / August 31, 2020 / CEL-SCI Corporation (NYSE American:CVM), a Phase 3 cancer immunotherapy company, today announced that it will be presenting at the LD 500 investor conference...

CVM : 13.19 (-1.71%)
CEL-SCI Corporation Reports Third Quarter Fiscal 2020 Financial Results

CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended June 30, 2020 and provided an update on clinical developments:

CVM : 13.19 (-1.71%)
CEL-SCI to Present at H.C. Wainwright Virtual Fireside Chat Series

CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, announced today that Geert Kersten, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright...

CVM : 13.19 (-1.71%)
CEL-SCI Corporation Reports Second Quarter Fiscal 2020 Financial Results

CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended March 31, 2020 and provided an update on clinical developments:

CVM : 13.19 (-1.71%)
CEL-SCI's Pivotal Phase 3 Study Has Reached the Required Number of Events to Evaluate Data for Multikine in Treatment of Head and Neck Cancer

CEL-SCI Corporation (NYSE American: CVM) announced today that it has been notified that it has reached the targeted threshold of 298 events (deaths) required to conduct the data evaluation for its pivotal...

CVM : 13.19 (-1.71%)
CEL-SCI Reports Recent Data Review by the Independent Data Monitoring Committee for Its Pivotal Phase 3 Head and Neck Cancer Study

CEL-SCI Corporation (NYSE American: CVM) announced today that the Independent Data Monitoring Committee (IDMC) for the Company's pivotal Phase 3 head and neck cancer study of its investigational immunotherapy...

CVM : 13.19 (-1.71%)
Important Update For CEL-SCI Corporation Annual Meeting of Shareholders

CEL-SCI Corporation (NYSE American: CVM), announced today that there are now two options to access the virtual meeting webcast. You may join as a "Guest" or join as a "Shareholder". If you join as a "Shareholder"...

CVM : 13.19 (-1.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade CVM with:

Business Summary

CEL-SCI CORP. was formed to acquire and finance research and development of natural human interleukin-2 (``IL-2``) and lymphokine-related products and processes using the Co.'s proprietary cell culture technologies. The Co.'s proprietary product is sometimes referred to as MULTIKINEn, or buffy-coat interleukins,...

See More

Key Turning Points

2nd Resistance Point 14.08
1st Resistance Point 13.75
Last Price 13.19
1st Support Level 13.12
2nd Support Level 12.82

See More

52-Week High 18.00
Fibonacci 61.8% 13.42
Last Price 13.19
Fibonacci 50% 12.00
Fibonacci 38.2% 10.58
52-Week Low 6.00

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar